ClinicalTrials.gg
CompletedNCT01433263Updated Mar 2, 2016Results posted

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

A Phase 2 interventional study of BYM338 active drug and Placebo in Cachexia, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.

Enrollment
31st of 72
57 · median 51
Started
2011
with 3 others
Phase 2
24 of 95
2 open now
Registered
46th of 95
by date
Lead sponsor
3 of 95
Novartis Pharmaceuticals

Among the 95 studies in Cachexia with a site in United States, this one is the 31st largest by enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2011, is one of 24 in phase 2, and was the 46th registered.

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

Browse Cachexia studies →

Open to participants now

9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Cachexia with a site in United States, or all of them as a file.
02

Study summary

A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas

03

Conditions studied

  • Cachexia

Keywords

  • Wasting syndrome
  • emaciation
  • lung cancer
  • adenocarcinoma
  • pancreatic cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  1. Patients must sign an before assessment
  2. Patients with pathologically and/or clinically confirmed diagnosis of stage IV non-small (squamous or non-squamous) cell lung cancer (NSCLC) or stage III/IV adenocarcinoma of the pancreas.
  3. Patients with stage IV NSCLC will be receiving or completed or discontinued standard chemotherapy or be chemotherapy-naive by choice.
  4. Patients with stage III/IV pancreatic adenocarcinoma will be receiving standard chemotherapy or no chemotherapy. If patients are receiving chemotherapy, a change in chemotherapy is not expected.
  5. Greater than or equal to 5% unintentional weight loss over the previous 3-6 months, not explained by simple starvation. Simple starvation is considered to be excluded when weight loss is not ameliorated by standard nutritional counseling and oral supplementation over a 2 week period.
  6. (BMI) ≤ 30 kg/m2.
  7. of at least 4 months.
  8. Able to communicate well and comply with the requirements of the study, including by phone and written logs.

Key Exclusion criteria:

  1. Patients who have received anti-neoplastic therapy within 3 weeks of screening
  2. Evidence of inadequate organ or brain function, as defined by lab tests and imaging
  3. Patients with severe and/or uncontrolled medical conditions that could interfere with the study (e.g. heart conditions, high blood pressure, diabetes, infection) uncontrolled pain or any other non-stable illness
  4. Pregnant or lactating women.
  5. Women capable of becoming pregnant must use highly effective during the study and for 8 weeks after stopping treatment. All female patients must have negative pregnancy test results throughout the study
  6. Patients unwilling or unable to follow instructions.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    30mg/kg BYM338

    Drug: BYM338 active drug

  • Placebo comparator
    Placebo / late 30mg/kg BYM338

    Drug: BYM338 active drug · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8

    Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 8 was considered responders.

    Time frame: Baseline, week 8

Secondary outcomes

  1. Percentage Change in Body Weight From Baseline at Week 7 and Week 9

    Percentage Change in body weight from baseline in killograms (kg) at week 7 and week 9

    Time frame: Baseline, Week 7 and Week 9

  2. Maximum Observed Serum Concentration (Cmax)

    Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

    Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 1 and Week 8

  3. Time to Reach the Maximum Concentration After Drug Administration (Tmax)

    Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). Tmax was directly determined from the raw serum concentration-time data.

    Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 1 and Week 8

  4. Percentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 8

    total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(LBM at Visit - LBM at Baseline) / LBM at Baseline\] \* 100.

    Time frame: Baseline, Week 8

  5. Percentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 8

    Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

    Time frame: Baseline, Week 8

  6. Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7

    Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.

    Time frame: Baseline, Week 4 and Week 7

  7. Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Sedentary Taken Compared to Placebo at Week 4 and 7

    Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.

    Time frame: Baseline, Week 4 and Week 7

  8. Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Standing Compared to Placebo at Week 4 and 7

    Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.

    Time frame: Baseline, Week 4 and Week 7

  9. Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Stepping Compared to Placebo at Week 4 and 7

    Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.

    Time frame: Baseline, Week 4 and Week 7

07

Results

Posted May 13, 2015

Participant flow

Core Phase single dose BYM338 30mg/kg i.v. active or placebo with 8week followup. Followup phase started Week 8 \& patients on placebo in the Core Phase were given BYM338 \& patients on BYM338 in Core Phase continued to be followed for an additional 8 weeks. Late BYM338 are patients who received Placebo during Core Phase and then BYM338 after Week 8.

Participant flow — Overall Study
Milestone30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Started2928
Completed1016
Not completed1912
Withdrew: Adverse event31
Withdrew: Death53
Withdrew: Lost to follow-up01
Withdrew: Protocol deviation10
Withdrew: Withdrawal by subject107

Outcome measures

PrimaryPercentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8

Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 8 was considered responders.

Time frame:
Baseline, week 8
Reported as:
Mean · Percentage Change of TMV
Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8
Percentage Change of TMV30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 82.0 ± 8.0940.65 ± 8.239
SecondaryPercentage Change in Body Weight From Baseline at Week 7 and Week 9

Percentage Change in body weight from baseline in killograms (kg) at week 7 and week 9

Time frame:
Baseline, Week 7 and Week 9
Reported as:
Mean · Percent Change of Weight (kg)
Percentage Change in Body Weight From Baseline at Week 7 and Week 9
Percent Change of Weight (kg)30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Week 7 (n= 15, 17)-3.3 ± 5.035-0.68 ± 4.457
Week 9 (n=14,16)-1.8 ± 7.131-0.32 ± 3.271
SecondaryMaximum Observed Serum Concentration (Cmax)

Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Time frame:
0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 1 and Week 8
Reported as:
Mean · ng/ml
Maximum Observed Serum Concentration (Cmax)
ng/ml30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Maximum Observed Serum Concentration (Cmax)422 ± 142408 ± 78.4
SecondaryTime to Reach the Maximum Concentration After Drug Administration (Tmax)

Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). Tmax was directly determined from the raw serum concentration-time data.

Time frame:
0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 1 and Week 8
Reported as:
Median · hr
Time to Reach the Maximum Concentration After Drug Administration (Tmax)
hr30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Time to Reach the Maximum Concentration After Drug Administration (Tmax)2.05 ± 1422.22 ± 78.4
SecondaryPercentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 8

total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(LBM at Visit - LBM at Baseline) / LBM at Baseline\] \* 100.

Time frame:
Baseline, Week 8
Reported as:
Mean · Percentage Change in LBM
Percentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 8
Percentage Change in LBM30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Percentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 84.97 ± 7.5372.41 ± 4.625
SecondaryPercentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 8

Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.

Time frame:
Baseline, Week 8
Reported as:
Mean · Percentage Change in BMD
Percentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 8
Percentage Change in BMD30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Percentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 80.51 ± 3.7120.14 ± 4.14
SecondaryPercentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7

Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.

Time frame:
Baseline, Week 4 and Week 7
Reported as:
Mean · percentage change in number of steps
Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7
percentage change in number of steps30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Week 4 (n=18, 23)917.78 ± 3720.49163.59 ± 130.913
Week 7 (n=13, 22)-17.37 ± 80.35035.80 ± 119.486
SecondaryPercentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Sedentary Taken Compared to Placebo at Week 4 and 7

Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.

Time frame:
Baseline, Week 4 and Week 7
Reported as:
Mean · percentage change in time (minutes)
Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Sedentary Taken Compared to Placebo at Week 4 and 7
percentage change in time (minutes)30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Week 4 (n=18, 23)-0.05 ± 10.04952.25 ± 207.403
Week 7 (n=13, 22)107.85 ± 280.79160.25 ± 222.366
SecondaryPercentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Standing Compared to Placebo at Week 4 and 7

Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.

Time frame:
Baseline, Week 4 and Week 7
Reported as:
Mean · percentage change in time (minutes)
Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Standing Compared to Placebo at Week 4 and 7
percentage change in time (minutes)30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Week 4 (n=18, 23)1.82 ± 78.36438.17 ± 111.361
Week 7 (n=13, 22)41.90 ± 251.29123.76 ± 99.268
SecondaryPercentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Stepping Compared to Placebo at Week 4 and 7

Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.

Time frame:
Baseline, Week 4 and Week 7
Reported as:
Mean · percentage change in time (minutes)
Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Stepping Compared to Placebo at Week 4 and 7
percentage change in time (minutes)30mg/kg BYM338Placebo / Late 30mg/kg BYM338
Week 4 (n=18, 22)1446.69 ± 6011.32485.30 ± 159.949
Week 7 (n=13, 21)-31.64 ± 67.18033.39 ± 129.218

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Core - 30mg/kg BYM338—18/29 (62.1%)19/29 (65.5%)
Core - Placebo—4/28 (14.3%)19/28 (67.9%)
Follow-up - 30mg/kg BYM338—7/19 (36.8%)12/19 (63.2%)
Follow-up - Placebo—1/3 (33.3%)2/3 (66.7%)
Follow-up - 30mg/kg BYM338 Late—7/21 (33.3%)13/21 (61.9%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventCore - 30mg/kg BYM338Core - PlaceboFollow-up - 30mg/kg BYM338Follow-up - PlaceboFollow-up - 30mg/kg BYM338 Late
NauseaGastrointestinal disorders0/290/280/191/30/21
VomitingGastrointestinal disorders0/290/280/191/30/21
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/290/283/190/31/21
DehydrationMetabolism and nutrition disorders3/290/280/190/30/21
AnaemiaBlood and lymphatic system disorders2/290/280/190/30/21
Urinary tract infectionInfections and infestations2/290/280/190/30/21
Deep vein thrombosisVascular disorders2/290/280/190/30/21
DiplopiaEye disorders0/290/281/190/30/21
Disease progressionGeneral disorders0/291/281/190/30/21
InfectionInfections and infestations0/290/281/190/30/21
Most frequent other events
Showing 10 of 69
Most frequent other events
EventCore - 30mg/kg BYM338Core - PlaceboFollow-up - 30mg/kg BYM338Follow-up - PlaceboFollow-up - 30mg/kg BYM338 Late
AnaemiaBlood and lymphatic system disorders4/296/282/191/33/21
AscitesGastrointestinal disorders2/291/281/191/31/21
ConstipationGastrointestinal disorders2/291/280/191/30/21
DysphagiaGastrointestinal disorders0/291/280/191/31/21
FatigueGeneral disorders6/293/284/191/31/21
DizzinessNervous system disorders2/290/280/191/31/21
ErythemaSkin and subcutaneous tissue disorders1/290/280/191/30/21
DiarrhoeaGastrointestinal disorders5/293/281/190/35/21
NauseaGastrointestinal disorders5/291/280/190/32/21
VomitingGastrointestinal disorders4/291/280/190/32/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)30mg/kg BYM338Placebo / Late 30mg/kg BYM338Total
Mean62.8 ± 10.1761.5 ± 10.7462.1 ± 10.38
Sex: Female, Male
Sex: Female, Male(Participants)30mg/kg BYM338Placebo / Late 30mg/kg BYM338Total
Female9615
Male202242
08

Study locations

10 sites
  • Novartis Investigative Site
    Tucson, Arizona 85715, United States
  • Novartis Investigative Site
    Tampa, Florida 33647, United States
  • Novartis Investigative Site
    Chicago, Illinois 60611-3308, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Canton, Ohio 44718, United States
  • Novartis Investigative Site
    San Antonio, Texas 78217, United States
  • Novartis Investigative Site
    Vilnius, LT 08661, Lithuania
  • Novartis Investigative Site
    Bucharest, Sector 5, Romania
  • Novartis Investigative Site
    St. Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Edinburgh, EH10 5HF, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2011
First posted
Sep 13, 2011
Start
Aug 2011
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
May 13, 2015
Last update
Mar 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01433263
Responsible party
Sponsor
First posted
Sep 13, 2011
Start date
Aug 2011
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
May 13, 2015
Last update
Mar 2, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion